Microarray analysis for Glioblastoma drug-repositioning

Background: Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord.Glioblastoma forms from cells called astrocytes that support nerve cells. Glioblastoma can occur at any agebut tends to occur more often in older adults. One of the most important things to treat this type of braincancer is an appropriate drug, but drug discovery is a high-priced pipeline that may be taken a long time toachieve a good component that satisfies most of the pharmacokinetic assays for our interested disease. Oneway to reach this aim is the drug repositioning that we investigate in this research.Materials and Methods: We downloaded GSE۴۲۹۰ from the GEO database for our purpose and did ananalysis on it by R. After that we extracted genes that had high expression by setting LogFc >۱ and adj.p.val< ۰.۰۵. These genes did input as queries on the Enrichr web tool for investigating diseases pathway that thesegenes have an effect on them. One of the diseases based on the KEGG ۲۰۲۱ Human, was small cell lungcancer. We search on ChEMBL for small cell lung cancer relative compounds.Results: by filtering on the ChEMBL results based on the Lipinski and Ghose, drug-likeness roles, wecompared the SMILE structures of TALAZOPARIB which is accessible by results filtering, andEVEROLIMUS that is used for Glioblastoma treating, on the Swiss ADME. The TALAZOPARIB satisfiesall Drug-likeness assays than EVEROLIMUS and based on the ChEMBL references TALAZOPARIB isused for treating many types of cancers, so we can use instead of EVEROLIMUS.Conclusion: When drug discovery has a huge financial load on drug companies, drug repositioning is a goodand fast choice for them to provide the best drug component with satisfying most of the pharmacokineticassays and drug-likeness roles.

Keywords:

Glioblastoma , Drug repositioning , drug discovery , cancer